Efficacy and safety of baricitinib in 446 patients with rheumatoid arthritis: a real-life multicentre study

医学 类风湿性关节炎 内科学 甲氨蝶呤 不利影响 队列 托法替尼 胃肠病学
作者
Giacomo Maria Guidelli,Ombretta Viapiana,Nicoletta Luciano,Maria De Santis,Nicola Boffini,Luca Quartuccio,Domenico Birra,Edoardo Conticini,Maria Sole Chimenti,Chiara Bazzani,E Bruschi,Marta Riva,Lorenzo Maria Canziani,Gerolamo Bianchi,Maria Rosa Pozzi,Massimiliano Limonta,Roberto Gorla,Roberto Perricone,Bruno Frediani,Paolo Moscato
出处
期刊:Clinical and Experimental Rheumatology [Springer Vienna]
卷期号:39 (4): 868-873 被引量:34
标识
DOI:10.55563/clinexprheumatol/pudtpo
摘要

Baricitinib, an oral Janus kinase (JAK) 1-2 inhibitor, is currently used along biologic DMARDs (bDMARDs) after the failure of methotrexate (MTX) in rheumatoid arthritis (RA). We investigated the efficacy and safety of baricitinib in real life.We prospectively enrolled 446 RA patients treated with baricitinib from 11 Italian centres. Patients were evaluated at baseline and after 3, 6, and 12 months. They were arrayed based on previous treatments as bDMARD-naïve and bDMARD-insufficient responders (IR) after the failure or intolerance to bDMARDs. A sub-analysis differentiated the effects of methotrexate (MTX) and the use of oral glucocorticoids (OGC).Our cohort included 150 (34%) bDMARD-naïve and 296 (66%) bDMARD-IR patients, with 217 (49%) using baricitinib as monotherapy. Considering DAS-28-CRP as the primary outcome, at 3 and 6 months, 114/314 (36%) and 149/289 (51.6%) patients achieved remission, while those in low disease activity (LDA) were 62/314 (20%) and 46/289 (15.9%), respectively; finally at 12 months 81/126 (64%) were in remission and 21/126 (17%) in LDA. At all-timepoints up to 12 months, bDMARDs-naïve patients demonstrated a better clinical response, independently of MTX. A significant reduction in the OGC dose was observed at 3 and 12 months in all groups. The serum positivity for both rheumatoid factors (RF) and anti-citrullinated protein antibodies (ACPA) conferred a lower risk of stopping baricitinib due to inefficacy. Fifty-eight (13%) patients discontinued baricitinib due to adverse events, including thrombotic events and herpes zoster reactivation.Real-life data confirm the efficacy and safety profiles of baricitinib in patients with RA and provide evidence that drug survival is higher in bDMARDs-naïve and seropositive patients.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
南方姑娘发布了新的文献求助30
刚刚
小米布朗尼完成签到,获得积分10
刚刚
洛尚发布了新的文献求助10
刚刚
syvshc的应助被致行采纳,获得10
1秒前
Lucas的应助被夹心采纳,获得10
1秒前
EIO团队完成签到 ,获得积分10
1秒前
酷波er的应助被肖馨余采纳,获得10
1秒前
1秒前
荼蘼发布了新的文献求助10
2秒前
李桢发布了新的文献求助10
2秒前
2秒前
XUHAO发布了新的文献求助10
2秒前
li完成签到,获得积分10
2秒前
meng发布了新的文献求助30
3秒前
3秒前
柏舟发布了新的文献求助10
3秒前
哈哈哈哈发布了新的文献求助10
3秒前
zz不爱读书完成签到,获得积分10
3秒前
鲤鱼一手完成签到,获得积分10
3秒前
完美世界的应助被Peasein采纳,获得10
3秒前
zhen完成签到,获得积分10
3秒前
领导范儿的应助被聂裕铭采纳,获得10
3秒前
冷艳凌晴完成签到,获得积分20
4秒前
结实机器猫完成签到,获得积分10
4秒前
科研通AI6.4的应助被独特流沙采纳,获得10
4秒前
小蘑菇的应助被HW采纳,获得10
4秒前
4秒前
4秒前
DW的应助被molik采纳,获得10
4秒前
4秒前
123发布了新的文献求助10
4秒前
图图完成签到,获得积分10
4秒前
5秒前
小狮子完成签到,获得积分10
5秒前
共享精神的应助被米米采纳,获得10
5秒前
5秒前
5秒前
Jasper的应助被开朗的语风采纳,获得10
5秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8174559
求助须知:如何正确求助?哪些是违规求助? 9566586
关于积分的说明 21787112
捐赠科研通 7768831
什么是DOI,文献DOI怎么找? 3431746
关于科研通互助平台的介绍 2555956
邀请新用户注册赠送积分活动 2477100